Document:

<PAGE>   1
                                                                    EXHIBIT 10.1

                 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION

                                 BY AND BETWEEN

                    BIODELIVERY SCIENCES INTERNATIONAL, INC.

                                       AND

                           BIODELIVERY SCIENCES, INC.
<PAGE>   2
                 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION

         This AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this "Agreement")
is made and entered into as of July __, 2001 by and between BioDelivery Sciences
International, Inc., an Indiana corporation ("BDSI") and BioDelivery Sciences,
Inc., a Delaware corporation ("BDS").

                                    RECITALS

         A.       The Boards of Directors of BDS and BDSI believe that it is in
the best interests of each company and their respective stockholders that BDS
and BDSI combine into a single company through the statutory merger of BDS with
and into BDSI (the "Merger") and, in furtherance thereof, have approved the
Merger.

         B.       Pursuant to the Merger, among other things, the outstanding

shares of Common Stock of BDS ("BDS Common Stock") shall be converted into
shares of Common Stock of BDSI ("BDSI Common Stock"), as determined herein and
the outstanding shares of restricted Common Stock of BDS ("BDS Delta Stock")
issued pursuant to that certain Restricted Stock Plan of BioDelivery Sciences,
Inc. (the "BDS Delta Stock Plan") shall be converted into shares of restricted
BDSI Common Stock ("BDSI Delta Stock") issued pursuant to that certain
Restricted Stock Plan of BioDelivery Sciences International, Inc. (the "BDSI
Delta Stock Plan"). Unless the context indicates otherwise, when used herein,
the term "BDS Common Stock" shall include the shares of BDS Delta Stock; the
term "BDSI Common Stock" shall include the shares of BDSI Delta Stock; and the
term "BDS Stockholder" shall mean any holder of BDS Common Stock.

         C.       BDS and BDSI desire to make certain representations and
warranties and other agreements in connection with the Merger.

         D.       The parties intend, by executing this Agreement, to adopt a
plan of liquidation and merger of a subsidiary within the meaning of Sections
332 and 368(a)(i)(A) of the Internal Revenue Code of 1986, as amended (the
"Code").

         NOW, THEREFORE, in consideration of the covenants, promises and
representations set forth herein, and for other good and valuable consideration,
the parties agree as follows:

                                   ARTICLE I
                                   THE MERGER

         1.1      THE MERGER. At the Effective Time (as defined in Section 1.2)
and subject to and upon the terms and conditions of this Agreement, and the
corporate laws of the States of Delaware and Indiana, BDS shall be merged with
and into BDSI. The separate corporate existence of BDS shall cease and BDSI
shall continue as the surviving corporation. BDSI, as the surviving corporation
after the Merger, is hereinafter sometimes referred to as the "Surviving
Corporation."

         1.2      EFFECTIVE TIME. As promptly as practicable after the
satisfaction or waiver of the conditions set forth in Article VI, the parties
hereto shall cause the Merger to be consummated

<PAGE>   3
                                                                               2

by filing a Certificate of Merger (the "Certificate of Merger") with the
Secretary of State of the State of Delaware and the Secretary of State of the
State of Indiana (the time of such filing being the "Effective Time"). The
closing of the transactions contemplated hereby (the "Closing") shall take place
on or before November 1, 2001, at 10:00 a.m. at the offices of Stroock & Stroock
& Lavan LLP, 180 Maiden lane, New York, New York 10038 on the date of the
Effective Time (the "Closing Date") or at such other location as the parties may
mutually agree.

         1.3      EFFECT OF THE MERGER. At the Effective Time, the effect of the
Merger shall be as provided under Delaware Law and Indiana Law. Without limiting
the generality of the foregoing, and subject thereto, at the Effective Time all
the property, rights, privileges, powers and franchises of BDS shall vest in the
Surviving Corporation, and all debts, liabilities and duties of BDS shall become
the debts, liabilities and duties of the Surviving Corporation.

         1.4      ARTICLES OF INCORPORATION OF BDSI. The articles of
incorporation of BDSI in effect immediately prior to the Effective Time shall
become the articles of incorporation of the Surviving Corporation until amended
in accordance with applicable law.

         1.5      BYLAWS. The bylaws of BDSI in effect immediately prior to the
Effective Time shall become the bylaws of the Surviving Corporation until
amended in accordance with applicable law.

         1.6      DIRECTORS AND OFFICERS. From and after the Effective Time,
until successors are duly elected or appointed and qualified in accordance with
applicable law, (a) the directors of BDSI at the Effective Time shall become the
directors of the Surviving Corporation, and (b) the officers of BDSI at the
Effective Time shall become the officers of the Surviving Corporation.

         1.7      EMPLOYMENT AGREEMENTS. At or prior to the Effective Time, BDSI
shall extend to each key employee of BDS, as identified by the Board of
Directors of BDS, who is not already an employee under a written employment
agreement with BDSI, an employment opportunity and agreement with BDSI, in form
and substance as determined by BDSI, but which shall not be less favorable than
such employee's current employment arrangement with BDS.

         1.8      CONVERSION OF CAPITAL STOCK

                  (A)      CONVERSION OF BDS COMMON STOCK. Each share of BDS
Common Stock issued and outstanding immediately prior to the Effective Time,
other than any Dissenting Shares (as defined and to the extent provided in
Section 1.9(a)), will be canceled and extinguished and be converted
automatically into the right to receive 1.33 shares of BDSI Common Stock upon
surrender of the certificate representing such share of BDS Common Stock in the
manner provided in Section 1.10.

                  (B)      BDS DELTA STOCK. Each share of BDSI Delta Stock shall
be issued on the same terms and conditions as those applicable to the BDS Delta
Stock being replaced thereby, except that the "Delta" will be adjusted to $1.50
per share to reflect the Exchange Ratio and except as otherwise provided in the
BDSI Delta Stock Plan. BDSI represents, warrants and agrees that the BDSI Delta
Stock Plan, which will be adopted prior to the Effective Time, will be the same
in all material respects as the BDS Delta Stock Plan.

<PAGE>   4
                                                                               3

                  (C)      STOCK OPTIONS. At the Effective Time, there shall be
no options to purchase BDS Common Stock.

                  (D)      FRACTIONAL SHARES. No fraction of a share of BDSI
Common Stock will be issued, but in lieu thereof, each BDS Stockholder who would
otherwise be entitled to a fraction of a share of BDSI Common Stock (after
aggregating all fractional shares of BDSI Common Stock to be received by such
holder) shall be entitled to receive from BDSI a whole share of BDSI Common
Stock.

                  (E)      EXCHANGE RATIO. The "Exchange Ratio" shall mean the
ratio of 1.33 shares of BDSI Common Stock to be issued hereunder for one share
of BDS Common Stock to be surrendered pursuant to this Agreement.

                  (F)      BDSI HOLDINGS OF BDS CAPITAL STOCK. Notwithstanding
anything to the contrary herein contained, the 175,000 shares of BDS Common
Stock and the 273,200 shares of Series A Convertible Preferred Stock of BDS held
by BDSI (as well as any additional shares of capital stock of BDS that BDSI may
acquire after the date hereof) will be cancelled and extinguished in the Merger,
without any conversion. BDSI agrees that it will not transfer or otherwise
dispose of any of such shares prior to the Effective Time.

         1.9      DISSENTING SHARES.

                  (A)      Notwithstanding any provision of this Agreement to
the contrary, any shares of capital stock of BDS or BDSI held by a holder who
has demanded and perfected appraisal rights for such shares in accordance with
applicable Delaware Law or Indiana Law, as applicable, and who, as of the
Effective Time, has not effectively withdrawn such appraisal rights ("Dissenting
Shares"), shall not be converted into or represent a right to receive BDSI
Common Stock pursuant to Section 1.8, but the holder thereof shall only be
entitled to such rights as are granted by applicable law.

                  (B)      Notwithstanding the provisions of subsection (a), if
any holder of shares of capital stock of BDS who demands appraisal of such
shares under Delaware Law shall effectively withdraw the right to appraisal,
then, as of the later of the Effective Time and the occurrence of such event,
such holder's shares shall automatically be converted into and represent only
the right to receive BDSI Common Stock in accordance with the Exchange Ratio,
without interest thereon, upon surrender of the certificate representing such
shares.

                  (C)      BDS shall give BDSI: (i) prompt notice of any written
demands for appraisal of any shares of capital stock of BDS, withdrawals of such
demands, and any other instruments served pursuant to Delaware Law and received
by BDS; and (ii) the opportunity to participate in all negotiations and
proceedings which take place prior to the Effective Time with respect to demands
for appraisal under Delaware Law. BDS shall not, except with the prior written
consent of BDSI, voluntarily make any payment before the Effective Time with
respect to any demands for appraisal of capital stock of BDS or offer to settle
or settle any such demands.

<PAGE>   5
                                                                               4

        1.10     SURRENDER OF CERTIFICATES.

                  (A)      EXCHANGE AGENT. Prior to the Effective Time, BDSI
shall act as its own exchange agent (the "Exchange Agent") in the Merger.

                  (B)      BDSI TO PROVIDE BDSI COMMON STOCK. Promptly after the
Effective Time, BDSI shall make available for exchange in accordance with this
Article I the shares of BDSI Common Stock, issuable pursuant to Section 1.8, in
exchange for outstanding shares of BDS Stock.

                  (C)      EXCHANGE PROCEDURES. Promptly after the Effective
Time, the Surviving Corporation shall cause to be mailed to each holder of
record of a certificate or certificates (the "Certificates") which, immediately
prior to the Effective Time, represented outstanding shares of BDS Common Stock,
whose shares were converted into the right to receive shares of BDSI Common
Stock, pursuant to Section 1.8: (i) a letter of transmittal (which shall specify
that delivery shall be effected, and risk of loss and title to the Certificates
shall pass, only upon delivery of the Certificates to the Exchange Agent and
shall be in such form and have such other provisions as BDSI may reasonably
specify); and (ii) instructions for use in effecting the surrender of the
Certificates in exchange for certificates representing shares of BDSI Common
Stock. Upon surrender of a Certificate for cancellation to the Exchange Agent or
to such other agent or agents as may be appointed by BDSI, together with such
letter of transmittal, duly completed and validly executed in accordance with
the instructions thereto, the holder of such Certificate shall be entitled to
receive in exchange therefor, a certificate representing the number of whole
shares of BDSI Common Stock to which such holder is entitled pursuant to the
Exchange Ratio as defined in Section 1.6, and the Certificate so surrendered
shall forthwith be canceled. Until so surrendered, each outstanding Certificate
that, prior to the Effective Time, represented shares of BDS Common Stock will
be deemed from and after the Effective Time, for all corporate purposes, other
than the payment of dividends, to evidence the ownership of the number of full
shares of BDSI Common Stock into which such shares of BDS Common Stock shall
have been so converted in accordance with the Exchange Ratio as defined in
Section 1.6.

                  (D)      RESTRICTIONS ON TRANSFER. (i) Shares of BDSI Common
Stock issued to BDS Shareholders hereunder shall not be registered under the
Securities Act of 1933, as amended, and shall be subject to the following
restrictive legend which shall be affixed to each certificate.

       "THE SHARES OF COMMON STOCK (THE "SHARES") EVIDENCED BY THIS CERTIFICATE
       HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
       (THE "ACT") OR ANY STATE SECURITIES LAW. NO RESALES, PLEDGES,
       HYPOTHECATIONS OR OTHER TRANSFERS OF THE SHARES EVIDENCED BY THIS
       CERTIFICATE SHALL BE MADE AT ANY TIME WHATSOEVER, EXCEPT PURSUANT TO AN
       EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE
       SECURITIES LAWS OR UPON THE ISSUANCE OF A FAVORABLE OPINION OF THE
       CORPORATION'S LEGAL COUNSEL OR OF LEGAL COUNSEL ACCEPTABLE TO THE
       CORPORATION THAT THE RESALE, PLEDGE, HYPOTHECATION OR OTHER TRANSFER OF
       SUCH SHARES SHALL NOT BE IN VIOLATION OF THE ACT, OR ANY STATE SECURITIES
       ACT."

                  (ii)     Additionally, the shares of BDSI Delta Stock to be
issued hereunder shall bear the following legends:

<PAGE>   6
                                                                               5

       "THE SHARES EVIDENCED BY THIS CERTIFICATE AND THE TRANSFER OF THE SHARES
       ARE SUBJECT TO THE RESTRICTED STOCK PLAN OF BIO-DELIVERY SCIENCES
       INTERNATIONAL, INC. AND THE AGREEMENT BETWEEN THE CORPORATION AND THE
       REGISTERED HOLDER OF THE SHARES THAT IS CONTEMPLATED THEREBY.

                  (E)      TRANSFERS OF OWNERSHIP. If any certificate for shares
of BDSI Common Stock is to be issued in a name other than that in which the
certificate surrendered in exchange therefor is registered, it will be a
condition of the issuance thereof that the certificate so surrendered will be
properly endorsed and otherwise in proper form for transfer and that the person
requesting such exchange will have paid to BDSI or any agent designated by it
any transfer or other taxes required by reason of the issuance of a certificate
for shares of BDSI Common Stock in any name other than that of the registered
holder of the certificate surrendered, or established to the satisfaction of
BDSI or any agent designated by it that such tax has been paid or is not
payable.

         1.11     NO FURTHER OWNERSHIP RIGHTS IN BDS COMMON STOCK. All shares of
BDSI Common issued upon the surrender for exchange of shares of BDS Common Stock
in accordance with the terms hereof (including any cash paid in respect thereof)
shall be deemed to have been issued in full satisfaction of all rights
pertaining to such shares of BDS Common Stock, and there shall be no further
registration of transfers on the records of the Surviving Corporation of shares
of BDS Common Stock which were outstanding immediately prior to the Effective
Time. If, after the Effective Time, Certificates are presented to the Surviving
Corporation for any reason, they shall be canceled and exchanged as provided in
this Article I.

         1.12     LOST, STOLEN OR DESTROYED CERTIFICATES. In the event any
certificates evidencing shares of BDS Common Stock shall have been lost, stolen
or destroyed, the Exchange Agent shall issue in exchange for such lost, stolen
or destroyed certificates, upon the making of an affidavit of that fact by the
holder thereof, such shares of BDSI Common Stock pursuant to Section 1.8;
provided, however, that BDSI may, in its discretion and as a condition precedent
to the issuance thereof, require the owner of such lost, stolen or destroyed
certificates to deliver a bond in such sum as it may reasonably direct as
indemnity against any claim that may be made against BDSI or the Exchange Agent
with respect to the certificates alleged to have been lost, stolen or destroyed.

         1.13     TAX CONSEQUENCES AND ACCOUNTING TREATMENT. It is intended by
the parties hereto that the Merger shall constitute a merger and liquidation of
BDS within the meaning of Sections 332 and 368(a)(i)(A) of the Code and that the
transaction be accounted for as a purchase of a minority interest.

         1.14     TAKING OF NECESSARY ACTION; FURTHER ACTION. If, at any time
after the Effective Time, any such further action is necessary or desirable to
carry out the purposes of this Agreement and to vest in the Surviving
Corporation the full right, title and possession to all assets, property,
rights, privileges, powers and franchises of BDS, the officers and directors of
BDS and BDSI are fully authorized in the name of their respective corporations
or otherwise to take, and will take, all such lawful and necessary action.

<PAGE>   7
                                                                               6

                                   ARTICLE II
                      REPRESENTATIONS AND WARRANTIES OF BDS

         BDS hereby makes the following representations and warranties to BDSI.
All representations and warranties are to the best knowledge and belief of BDS.

         2.1      ORGANIZATION OF BDS. BDS (a) is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware;
and (b) has all corporate power and authority and all governmental licenses,
permits, authorizations, consents and approvals to own and lease its properties
and assets and to carry on its business as presently conducted.

         2.2      AUTHORIZATION; ENFORCEABILITY. BDS has, subject to shareholder
approval, full corporate power and authority to enter into this Agreement, to
consummate the transactions contemplated hereby, and to perform its obligations
hereunder. This Agreement has been executed and delivered by a duly authorized
officer of BDS and approved by the Board of Directors of BDS and, upon approval
by BDS Shareholders, will constitute a legal, valid and binding obligation of
BDS, enforceable against BDS in accordance with its terms.

         2.3      NO BREACH OR VIOLATION. BDS' execution and delivery of this
Agreement, its compliance with and fulfillment of the terms of this Agreement,
and its consummation of the transactions contemplated hereby, do not and will
not, with notice or passage of time or both, after giving effect to the
approvals, consents and other actions described on Schedule 2.3 attached hereto
(i) conflict with or result in a breach of the terms, conditions or provisions
of, (ii) constitute a default under, (iii) result in the creation of any
mortgage, lien, pledge, charge, security interest or encumbrance of any kind (a
"Lien") upon the capital stock, assets, properties or rights of BDS pursuant to,
(iv) give any Person the right to accelerate any obligation under, or (v) result
in a violation of, (a) any law, statute, code, ordinance, rule, regulation,
judgment, injunction, order, writ or decree (a "Law") applicable to BDS, (b)
BDS' certificate of incorporation or bylaws, (c) any material franchise, permit,
license, authorization, concession, order, judgment, writ, injunction or decree
to which BDS is subject, or by which any of its assets, properties or rights are
bound, or (d) any material lease, mortgage, indenture, deed of trust, trust
agreement, note agreement or other agreement or instrument to which BDS is
subject, or by which any of its assets, properties or rights are bound.

         2.4      LITIGATION. There is no litigation, suit, claim, action,
proceeding or investigation pending or, to BDS' knowledge, threatened by or
against BDS, whether at Law or in equity, before any nation or government, any
state or other political subdivision thereof, and any agency, department or
other entity exercising executive, legislative, judicial, regulatory or
administrative functions of or pertaining to government (a "Governmental
Authority") or before any arbitrator of any kind. Except as described on
Schedule 2.4, BDS has not been a party to any litigation, suit, claim, action,
proceeding or investigation during the past two years and it is not a party or
subject to any judgment, writ, injunction, order or decree.

         2.5      APPROVALS AND CONSENTS. No consent, approval, exemption,
audit, waiver, order or authorization of, or declaration, qualification,
designation, notice, filing or registration with, any governmental authority or
any other person, is required for BDS' execution and delivery of this Agreement,
the performance of its obligations hereunder, or its consummation of the
transactions contemplated herein.
<PAGE>   8
                                                                               7

         2.6      LABOR AGREEMENTS AND EMPLOYEE RELATIONS. BDS is not a party to
any collective bargaining or similar agreement covering any of its employees. No
labor organization or group of employees of BDS has made a demand for
recognition, has filed a petition seeking a representation proceeding, or given
BDS notice of any intention to hold an election of a collective bargaining
representative. BDS has not suffered any strike, slowdown, picketing or work
stoppage by any group of employees affecting its business.

         2.7      BROKERS' FEES. Neither BDS nor any person on BDS' behalf has
retained any broker, finder or agent or agreed to pay any brokerage fee,
finder's fee, commission or other payment with respect to the transactions
contemplated by this Agreement.

         2.8      ALL MATERIAL INFORMATION. The representations and warranties
made by BDS in this Agreement, including the attached schedules, and the
statements contained in any certificate or other instrument furnished to BDSI at
the Closing, do not contain any untrue statement of a material fact or knowingly
omit to state any material fact necessary in order to make any statement therein
not misleading.

         2.9      EMPLOYEE BENEFIT PLANS. Except as set forth on Schedule 2.9:

                  (A)      BDS does not, and does not have any obligation to,
maintain or contribute to any Employee Benefit Plan (as defined in Section 3(3)
of the Employee Retirement Income Security Act of 1974 (or any successor
legislation thereto), as amended from time to time and any regulations
promulgated thereunder ("ERISA")).

                  (B)      No event has occurred, and to BDS' knowledge, there
exists no condition or circumstances, in connection with which BDS could be
subject to any liability under the terms of any Employee Benefit Plan of BDS,
ERISA, the Code or any other applicable law which would have a material adverse
effect on its business.

                  (C)      The execution, delivery and performance of this
Agreement will not result in any: (i) increase in the compensation or benefits
otherwise payable under any Employee Benefit Plan of BDS or pursuant to any
agreement with respect to any employee of BDS; (ii) acceleration of the time of
payment or vesting of any such compensation or benefits due to any employee of
BDS; or (iii) renew or extend the term of any agreement regarding compensation
of any employee of BDS, which in the case of (i), (ii) or (iii) above, would
create any liability to BDSI after the Closing Date. No payment or benefit,
which may be made by BDS with respect to any employee of the BDS, will be
classified as an "excess parachute payment" within the meaning of Section 280G
of the Code.

         2.10     BENEFIT CLAIMS. BDS has no liability for any benefit which has
been or could be claimed as a result of any event occurring prior to the Closing
Date under any Employee Benefit Plan or any workers' compensation or similar law
(i) which is not fully covered by insurance, or (ii) if not so insured, for
which BDS has not established an adequate reserve on BDS's Financial Statements.

<PAGE>   9
                                                                               8

        2.11     OUTSTANDING STOCK AND OPTIONS. BDS has the shares of
outstanding capital stock and options and other rights to acquire shares of
Capital Stock of BDS as reflected on Schedule 2.11.

                                  ARTICLE III
                REPRESENTATIONS, WARRANTIES AND COVENANTS OF BDSI

         BDSI hereby represents, warrants and agrees with BDS as follows:

         3.1      EXISTENCE AND QUALIFICATION. BDSI (a) is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Indiana; (b) has all corporate power and authority and all governmental
licenses, permits, authorizations, consents and approvals to own and lease its
properties and assets and to carry on its business as presently conducted; and
(c) is duly qualified or licensed as a foreign corporation in, and is in good
standing under the laws of, each jurisdiction in which the nature or conduct of
its business or the character or location of its properties or assets requires
such qualification, except where the failure to be so qualified would not have
and would not reasonably be expected to have a material adverse effect.

         3.2      AUTHORIZATION; ENFORCEABILITY. BDSI has full corporate power
and authority to enter into this Agreement, to consummate the transactions
contemplated hereby, and to perform its obligations hereunder. This Agreement
has, subject to shareholder approval of BDSI, been executed and delivered by a
duly authorized officer of BDSI and approved by the Board of Directors of BDSI
and constitutes the legal, valid and binding obligation of BDSI enforceable
against BDSI in accordance with its terms.

         3.3      NO BREACH OR VIOLATION. BDSI's execution and delivery of this
Agreement, its compliance with and fulfillment of the terms of this Agreement,
and the consummation of the transactions contemplated hereby, do not and will
not, with notice or passage of time or both, after giving effect to the
approvals, consents and other actions described on Schedule 3.3 attached hereto
(i) conflict with or result in a breach of the terms, conditions or provisions
of, (ii) constitute a default or event of default under, (iii) result in the
creation of any lien upon any of the capital stock, assets, properties or rights
of BDSI pursuant to, (iv) give any person the right to accelerate any obligation
under, or (v) result in a violation of, (a) any law applicable to BDSI, (b)
BDSI's certificate of incorporation or bylaws, (c) any material franchise,
permit, license, authorization, concession, order, judgment, writ, injunction or
decree to which BDSI is subject, or by which any of its assets, properties or
rights are bound, or (d) any material lease, mortgage, indenture, deed of trust,
trust agreement, note agreement or other agreement, contract, understanding or
instrument to which BDSI is subject, or by which any of its assets, properties
or rights are bound.

         3.4      APPROVALS AND CONSENTS. Except as provided In Schedule 3.4, no
consent, approval, exemption, audit, waiver, order or authorization of, or
registration, qualification, designation, declaration, notice or filing with,
any governmental authority or any other person is required for BDSI's execution
and delivery of this Agreement, the performance of its obligations hereunder,
the assumption of the assumed obligations of BDS, or BDSI's consummation of the
other transactions contemplated herein.

<PAGE>   10
                                                                               9

        3.5      BROKERS' FEES. Neither BDSI nor any person on BDSI's behalf
has retained any broker, finder or agent or agreed to pay any brokerage fee,
finder's fee, commission or other payment with respect to the transactions
contemplated by this Agreement.

         3.6      COMPANY'S BUSINESS. BDSI has no material business operations
other than the business conducted by BDS. BDSI has no material assets other than
its shares of BDS Common Stock and has no material liabilities other than the
promissory notes issued to BDS pursuant to that certain Stock Purchase Agreement
dated as of September 5, 2000 by and between BDSI (f/k/a/ MAS Acquisition XXIII
Corp.) and BDS. BDSI will not take any action that will make this warranty
inaccurate or incomplete as of the Effective Time.

         3.7      ALL MATERIAL INFORMATION. The representations and warranties
made herein by BDSI, including the attached schedules, and the statements
contained in any certificate or other instrument furnished to BDS as required
herein do not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make any statement therein not
misleading.

         3.8      CAPITALIZATION.

                  (A)      The authorized capital stock of BDSI consists of (i)
80,000,000 shares of BDSI Common Stock, par value $.001 per share, and (ii)
20,000,000 shares of preferred stock, par value $.001 per share, of which
2,020,000 shares have been designated Series A Preferred Stock (the "BDSI
Preferred Stock"). As of the date of this Agreement, there are 16,350,000 shares
of BDSI Common Stock issued and outstanding, 2,020,000 shares of BDSI Common
Stock reserved for issuance upon the conversion of the BDSI Preferred Stock, no
shares of BDSI Common Stock reserved for issuance upon exercise of outstanding
options, and no shares of BDSI Common Stock held in the treasury of the Company.
As of the date of this Agreement, there are 2,020,000 shares of BDSI Preferred
Stock issued and outstanding. The Company has no bonds, debentures, notes or
other indebtedness having the right to vote on any matters on which holders of
BDSI Securities (as defined in paragraph (b) of this Section 3.8) may vote (such
items being referred to collectively as "Voting Debt") issued or outstanding.

                  (B)      All issued and outstanding shares of BDSI Common
Stock have been duly authorized and validly issued and are fully paid,
nonassessable and free of preemptive rights. All shares of BDSI Common Stock to
be issued in the Merger, when issued to the BDS Stockholders in accordance with
the terms of this Agreement, will be duly authorized, validly issued, fully
paid, nonassessable and free of preemptive rights. Except as set forth in
paragraph (a) of this Section 3.8, no Stock Rights (as defined below) are
authorized, issued or outstanding with respect to the capital stock of BDSI and
there are (x) no shares of capital stock or other voting securities of BDSI, (y)
no securities of BDSI convertible into or exchangeable for shares of capital
stock or voting securities of BDSI, and (z) no options or other rights to
acquire from BDSI, and no obligation of BDSI to issue, any capital stock, voting
securities or securities convertible into or exchangeable for capital stock or
voting securities (or cash or other property in lieu of such stock or
securities) of BDSI (the items in clauses (x), (y) and (z) being referred to
collectively as the "BDSI Securities"). There are no outstanding obligations of
BDSI to repurchase, redeem or otherwise acquire any BDSI Securities. For
purposes of this Agreement, "Stock Rights" mean warrants, options, rights,
convertible securities and other arrangements or

<PAGE>   11
                                                                              10

commitments which obligate an entity to issue or dispose of any of its capital
stock or any other equity security, and stock appreciation rights, performance
units and other similar stock-based rights whether they obligate the issuer
thereof to issue stock or other securities or to pay cash.

                  (C)      The capitalization of BDSI as set forth above will be
the same at the Effective Time, except (i) as modified to the extent necessary
to reflect the Exchange Ratio and (ii) that prior to the Effective Time, BDSI
will adopt the BDSI Delta Stock Plan and a stock option plan providing for the
issuance of up to 2,500,000 shares of BDSI Common Stock, such plan to be on
terms and conditions reasonably acceptable to BDS.

         3.9      FINANCIAL STATEMENTS.

                  (A)      BDSI has delivered to BDS, a draft of the
consolidated balance sheets of BDSI and its subsidiaries as of December 31, 1999
and 2000 and the related consolidated results of operations and statements of
cash flows and stockholders' equity for each of the corresponding years then
ended (the "Annual Financial Statements"). The Annual Financial Statements
fairly present, in conformity with United States generally accepted accounting
principles applied on a consistent basis ("GAAP"), the consolidated financial
position of BDSI and its subsidiaries as of the dates thereof and their
consolidated results of operations and statements of cash flows and
stockholders' equity for the periods then ended (subject to normal year-end
audit adjustments). Since December 31, 2000, BDSI has not prepared any interim
financial statements which would satisfy the requirements for being included in
Form 10-QSB.

                  (B)      Except as set forth in the Annual Financial
Statements (including any related notes and schedules thereto), neither BDSI nor
any of its subsidiaries had at December 31, 2000, or has incurred since that
date through the date hereof, and will not incur through the Effective Time, any
liabilities or obligations (whether absolute, accrued, contingent or otherwise)
of any nature, except (i) liabilities, obligations or contingencies which (A)
are accrued or reserved against in the Annual Financial Statements or reflected
in the notes thereto or (B) were incurred in the ordinary course of business and
consistent with past practices since December 31, 2000, and (ii) liabilities,
obligations and contingencies which are of a nature not required to be reflected
in the consolidated financial statements of BDSI and its subsidiaries prepared
in accordance with GAAP consistently applied.

         3.10     ABSENCE OF CERTAIN CHANGES. Except as disclosed in the Annual
Financial Statements or on Schedule 3.10 hereto, since December 31, 2000, the
Company and its subsidiaries have conducted their business in the ordinary
course in accordance with their customary practices, and there has not been and,
through the Effective Time, there will not be:

                  (A)      any event or occurrence which has had or reasonably
would be expected to have, individually or in the aggregate, any material
adverse change in the business, operations, prospects, assets, or condition
(financial or otherwise) of BDSI and its subsidiaries (other than BDS), taken as
a whole;

                  (B)      any declaration, setting aside or payment of any
dividend or other distribution with respect to any shares of capital stock of
BDSI, or any repurchase, redemption or other acquisition by BDSI or any of its
subsidiaries of any outstanding shares of capital stock or other securities of,
or other ownership interests in, BDSI;

<PAGE>   12
                                                                              11

                  (C)      any incurrence, assumption or guarantee by BDSI or
any of its subsidiaries of any outstanding amount of indebtedness for borrowed
money, or any creation or assumption by BDSI or any of its subsidiaries of any
Lien on any material asset, in each case other than in the ordinary course of
business in accordance with their customary practices;

                  (D)      any transaction or commitment made, or any contract
or agreement entered into, by BDSI or any of its subsidiaries (other than BDS)
relating to their respective assets or businesses (including the acquisition or
disposition of any assets) or any relinquishment by BDSI or any of its
subsidiaries (other than BDS) of any contract or other right, other than
transactions and commitments in the ordinary course of business in accordance
with their customary practices;

                  (E)      any damage, destruction or other casualty loss
(whether or not covered by insurance) affecting the business or assets of BDSI
or any of its subsidiaries (other than BDS);

                  (F)      any change in any method of accounting or accounting
practice or policy or application thereof by BDSI or any of its subsidiaries
(other than BDS);

                  (G)      any labor dispute, other than routine individual
grievances, or any activity or proceeding by a labor union or representative
thereof to organize any employees of BDSI or any of its subsidiaries (other than
BDS), or any lockouts, strikes, slowdowns, work stoppages or threats thereof by
or with respect to such employees.

                                   ARTICLE IV
                                OTHER AGREEMENTS

         4.1      INDEMNIFICATION; DIRECTORS AND OFFICERS INSURANCE.

                  (A)      All rights to indemnification and permitted
limitations of liability for monetary damages existing in favor of the present
or former directors officers and employees of BDS as provided in BDS's
certificate of incorporation or bylaws as in effect on the date hereof or
pursuant to any agreements previously disclosed by BDS in writing to BDSI, with
respect to matters occurring prior to the Effective Time (including without
limitation the transactions contemplated by this Agreement) shall survive the
Merger and shall continue in full force and effect (to the extent consistent
with applicable law) after the Effective Time, without material alteration or
amendment. After the Effective Time, BDSI shall indemnify, defend and hold
harmless the present and former directors and officers of BDS against all
losses, claims, damages or liabilities arising out of actions or omissions
occurring at or prior to the Effective Time (including without limitation the
transactions contemplated by this Agreement) to the full extent then permitted
under the Delaware General Corporation Law and by the BDS's certificate of
incorporation or bylaws as in effect on the date hereof; provided that such
indemnification shall be subject to any limitation imposed from time to time
under applicable law. Without limiting the foregoing, BDSI, to the extent
permitted by applicable law, will periodically advance expenses as incurred with
respect to the foregoing to the fullest extent permitted under applicable law;
provided that the person to whom the expenses are advanced provides an
undertaking to

<PAGE>   13
                                                                              12

repay such advances if it is ultimately determined that such person is not
entitled to indemnification.

                  (B)      In the event that BDSI or its successors or assigns
(i) consolidates with or merges into another person and shall not be the
continuing or surviving corporation or entity of such consolidation or merger or
(ii) transfers all or substantially all of its properties or assets to any
person, then in each such case, proper provisions shall be made so that the
successors and assigns of BDSI shall assume the obligations set forth in this
Section 3.11.

         4.2      PROMISSORY NOTE OBLIGATIONS. At the Effective Time, the
Surviving Corporation will forgive the promissory note indebtedness owed by BDS
Stockholders (excluding BDSI), together with accrued interest thereon, which
arose out of their purchase of BDS Common Stock. The Surviving Entity further
agrees to pay to each such BDS Stockholder no later than April 1, 2002, a bonus
equal to 65% of the amount of such stockholder's debt forgiven.

                                   ARTICLE V
                            CONDITIONS TO THE MERGER

         5.1      CONDITIONS TO OBLIGATIONS OF EACH PARTY TO EFFECT THE MERGER.
The respective obligations of each party to this Agreement to effect the Merger
shall be subject to the satisfaction at or prior to the Effective Time of the
following conditions:

                  (A)      STOCKHOLDER APPROVAL. This Agreement and the Merger
shall have been approved and adopted by the requisite vote of the stockholders
of BDS and BDSI.

                  (B)      NO INJUNCTIONS OR RESTRAINTS: ILLEGALITY. No
temporary restraining order, preliminary or permanent injunction or other order
issued by any court of competent jurisdiction or other legal restraint or
prohibition preventing the consummation of the Merger shall be in effect, nor
shall any proceeding brought by an administrative agency or commission or other
governmental authority or instrumentality, domestic or foreign, seeking any of
the foregoing be pending; nor shall there be any action taken, or any statute,
rule, regulation or order enacted, entered, enforced or deemed applicable to the
Merger, which makes the consummation of the Merger illegal.

                  (C)      Grant Thornton LLP, independent public accountants
for BDSI, shall have advised BDSI in writing that the transactions contemplated
hereby shall qualify as a liquidation and merger of a subsidiary within the
meaning of Sections 332 and 368(a)(i)(A) of the Code.

         5.2      ADDITIONAL CONDITIONS TO OBLIGATIONS OF BDS. The obligations
of BDS to consummate and effect this Agreement and the transactions contemplated
hereby shall be subject to the satisfaction at or prior to the Effective Time of
each of the following conditions, any of which may be waived, in writing,
exclusively by BDS:

                  (A)      REPRESENTATIONS, WARRANTIES AND COVENANTS. The
representations and warranties of BDSI in this Agreement shall be true and
correct in all material respects on and as of the Effective Time as though such
representations and warranties were made on and as of such time and BDSI shall
have performed and complied in all material respects with all covenants,

<PAGE>   14
                                                                              13

obligations and conditions of this Agreement required to be performed and
complied with by it as of the Effective Time.

                  (B)      CERTIFICATE OF BDSI. BDS shall have been provided
with a certificate executed on behalf of BDSI by its President or its Chief
Financial Officer or Treasurer to the effect that, as of the Effective Time:

                           (I)      All representations and warranties made by
BDSI under this Agreement are true and complete in all material respects; and

                           (II)     All covenants, obligations and conditions of
this Agreement to be performed by BDSI on or before such date have been so
performed in all material respects.

                  (C)      SATISFACTORY FORM OF LEGAL MATTERS. The form, scope
and substance of all legal matters contemplated hereby and all closing documents
and other papers delivered hereunder shall be reasonably acceptable to counsel
to BDS.

                  (D)      FINANCIAL STATEMENTS. The consolidated balance sheet,
the consolidated results of operations and statements of cash flows and
stockholders' equity of BDSI for each of the years ended December 31, 1999 and
2000, as reflected in BDSI's audited financial statements, will not be
materially different from the consolidated balance sheet, the consolidated
results of operations and statements of cash flows and stockholders' equity as
reflected in the Annual Financial Statements.

         5.3      ADDITIONAL CONDITIONS TO THE OBLIGATIONS OF BDSI. The
obligations of BDSI to consummate and effect this Agreement and the transactions
contemplated hereby shall be subject to the satisfaction at or prior to the
Effective Time of each of the following conditions, any of which may be waived,
in writing, exclusively by BDSI:

                  (A)      REPRESENTATIONS, WARRANTIES AND COVENANTS. The
representations and warranties of BDS in this Agreement shall be true and
correct in all material respects on and as of the Effective Time.

                  (B)      CERTIFICATE OF BDS. BDSI shall have been provided
with a certificate executed on behalf of BDS by its President or Chief Financial
Officer to the effect that, as of the Effective Time:

                           (I)      All representations and warranties made by
BDS under this Agreement are true and complete in all material respects; and

                           (II)     All covenants, obligations and conditions of
this Agreement to be performed by BDS on or before such date have been so
performed in all material respects.

         (C)      THIRD PARTY CONSENTS. Any and all consents, waivers and
approvals required from third parties relating to the contracts and agreements
of BDS so that the Merger and other transactions contemplated hereby do not
adversely affect the rights of, and benefits to, BDS thereunder shall have been
obtained.

         (D)      SATISFACTORY FORM OF LEGAL MATTERS. The form, scope and
substance of all legal matters contemplated hereby and all closing documents and
other papers delivered hereunder shall be reasonably acceptable to BDSI's
counsel.

<PAGE>   15
                                                                              14

                  (E)      DISSENTERS. The number of shares of BDS Common Stock
held by holders who either (i) have exercised appraisal rights or (ii) retain
the ability to exercise such appraisal rights shall not exceed an amount
reasonably acceptable to BDSI.

                                   ARTICLE VI
                   SURVIVAL OF REPRESENTATIONS AND WARRANTIES

         6.1      SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All covenants to
be performed prior to the Effective Time, and all representations and warranties
in this Agreement or in any instrument delivered pursuant to this Agreement
shall survive the Merger and continue in effect for a period of five (5) years
following Closing.

                                  ARTICLE VII
                        TERMINATION, AMENDMENT AND WAIVER

                  7.1      TERMINATION. This Agreement may be terminated and the
Merger abandoned at any time prior to the Effective Time:

                  (A)      By mutual consent of BDS and BDSI;

                  (B)      By BDSI if it is not in material breach of its
obligations under this Agreement and there has been a material breach of any
representation, warranty, covenant or agreement contained in this Agreement on
the part of BDS and such breach has not been cured within fifteen (15) days
after notice to BDS.

                  (C)      By BDS if it is not in material breach of its
obligations under this Agreement and there has been a material breach of any
representation, warranty, covenant or agreement contained in this Agreement on
the part of BDSI and such breach has not been cured within fifteen (15) days
after notice to BDSI;

                  (D)      By any party hereto if: (i) the Closing has not
occurred by November 1, 2001; (ii) there shall be a final nonappealable order of
a federal or state court in effect preventing consummation of the Merger; (iii)
there shall be any action taken, or any statute, rule, regulation or order
enacted, promulgated or issued or deemed applicable to the Merger by any
Governmental Entity which would make consummation of the Merger illegal; or (iv)
there shall be any action taken, or any statute, rule, regulation or order
enacted, promulgated or issued or deemed applicable to the Merger by any
Governmental Entity, which would (A) prohibit BDSI's or BDS' ownership or
operation of all or a material portion of the business of BDS, or compel BDSI or
BDS to dispose of or hold separate all or a material portion of the business or
assets of BDS or BDSI as a result of the Merger or (B) render BDSI or BDS unable
to consummate the Merger, except for any waiting period provisions.

<PAGE>   16
                                                                              15

         Where action is taken to terminate this Agreement pursuant to this
Section 7.1, it shall be sufficient for such action to be authorized by the
Board of Directors (as applicable) of the party taking such action.

         7.2      EFFECT OF TERMINATION. In the event of termination of this
Agreement as provided in Section 6.2, this Agreement shall forthwith become void
and there shall be no liability or obligation on the part of BDSI or BDS or
their respective officers, directors or stockholders, except if such termination
results from the breach by a party hereto of any of its representations,
warranties, covenants or agreements set forth in this Agreement.

         7.3      AMENDMENT. This Agreement may be amended by the parties hereto
at any time before or after approval of matters presented in connection with the
Merger by the stockholders of those parties required by applicable law to so
approve but, after any such stockholder approval, no amendment shall be made
which by law requires the further approval of stockholders of a party without
obtaining such further approval. This Agreement may not be amended except by an
instrument in writing signed on behalf of each of the parties hereto.

         7.4      EXTENSION; WAIVER. At any time prior to the Effective Time any
party hereto may, to the extent legally allowed, (i) extend the time for the
performance of any of the obligations or other acts of the other parties hereto,
(ii) waive any inaccuracies in the representations and warranties made to such
party contained herein or in any document delivered pursuant hereto and (iii)
waive compliance with any of the agreements or conditions for the benefit of
such party contained herein. Any agreement on the part of a party hereto to any
such extension or waiver shall be valid only if set forth in an instrument in
writing signed on behalf of such party.

                                  ARTICLE VIII
                               GENERAL PROVISIONS

         8.1      NOTICES. All notices and other communications hereunder shall
be in writing and shall be deemed given if delivered personally or by commercial
delivery service, or mailed by registered or certified mail (return receipt
requested) or sent via telecopy to the parties at the following addresses (or at
such other address for a party as shall be specified by like notice):

                  (A)      if to BDSI:

         To:      BioDelivery Sciences International, Inc.
                  Attention:  Francis E. O'Donnell, Jr., MD
                  709 The Hamptons Lane
                  Chesterfield, MO  63017
                  Fax:     (314) 534-7030

         Copy to:

                  Richard Joseph Salem, Esq.
                  P.O. Box 3399
                  Tampa, Florida 33601-3399
                  Fax:     (813) 221-8811
<PAGE>   17
                                                                              16

(B)      if to BDS

         To:      BioDelivery Sciences, Inc.
                  Attention: Raphael J. Mannino, PhD.
                  185 South Orange Avenue, BSB-A 691
                  Newark, NJ  07103
                  Fax:     (973) 972-0323

         Copy to:

                  Mel Epstein, Esq.
                  Stroock & Stroock & Lavan LLP
                  180 Maiden Lane
                  New York, NY  10038
                  Fax:     (212) 806-6006

         8.2      INTERPRETATION. When a reference is made in this Agreement to
Schedules or Exhibits, such reference shall be to a Schedule or Exhibit to this
Agreement unless otherwise indicated. The words "include," "includes" and
"including" when used herein shall be deemed in each case to be followed by the
words "without limitation." The table of contents and headings contained in this
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement.

         8.3      COUNTERPARTS. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each of
the parties and delivered to the other party, it being understood that all
parties need not sign the same counterpart.

         8.4      MISCELLANEOUS. This Agreement and the documents and
instruments and other agreements among the parties hereto (a) constitute the
entire agreement among the parties with respect to the subject matter hereof and
supersede all prior agreements and understandings, both written and oral, among
the parties with respect to the subject matter hereof; (b) are not intended to
confer upon any other person any rights or remedies hereunder except, in the
case of (i) Section 4.1, for the directors and officers of BDS referred to
therein and (ii) Section 4.2, for the BDS Stockholders referred to therein; and
(c) shall not be assigned by operation of law or otherwise except as otherwise
specifically provided.

         8.5      GOVERNING LAW. This Agreement shall be governed in all
respects, including validity, interpretation and effect, by the laws of the
State of Delaware. All parties hereto agree to submit to the jurisdiction of the
federal and state courts of the State of Delaware.

         8.6      ATTORNEYS' FEES. If any party to this Agreement brings an
arbitration action against another party to this Agreement to enforce its rights
under this Agreement, the prevailing party shall be entitled to recover its
reasonable costs and expenses, including reasonable attorneys' fees and costs,
incurred in connection with such action, including any appeal of such action.

<PAGE>   18
                                                                              17

         8.7      ARBITRATION. Except as otherwise provided in hereunder, any
controversy or claim arising out of or relating to this Agreement, or the breach
thereof, shall be settled by arbitration in accordance with the rules of the
American Arbitration Association, and judgment upon the award rendered by the
arbitrator(s) may be entered in any court having jurisdiction thereof.

         8.8      RULES OF CONSTRUCTION. The parties hereto agree that they have
been represented by counsel during the negotiation and execution of this
Agreement and, therefore, waive the application of any law, regulation, holding
or rule of construction providing that ambiguities in an agreement or other
document will be construed against the party drafting such agreement or
document.

<PAGE>   19
                                                                              18

         IN WITNESS WHEREOF, BDSI and the BDS Stockholders have caused this
Agreement to be signed by themselves or their duly authorized respective
officers, all as of the date first written above.

                                      BioDelivery Sciences International, Inc.

                                      By:
                                         ---------------------------------------
                                            Francis E. O'Donnell
                                            Chairman and Chief Executive Officer

         IN WITNESS WHEREOF, BioDelivery Sciences, Inc. has caused this
Agreement to be executed in its corporate name by its President as of the date
first written above.

                                      BioDelivery Sciences, Inc.

                                      By:
                                         --------------------------------------
                                            Raphael Mannino, Ph.D., President

<PAGE>   20
                                                                              19

                                  SCHEDULE 2.3
                                REQUIRED CONSENTS

         To BDS' knowledge, none. Any required notices under the Irv Berstein
settlement will be issued.

<PAGE>   21
                                                                              20

                                  SCHEDULE 2.4
                                   LITIGATION

                                      None.

<PAGE>   22
                                                                              21

                                  SCHEDULE 2.9
                             EMPLOYEE BENEFIT PLANS

                                      None.

<PAGE>   23
                                                                              22

                                  SCHEDULE 2.11
                          OUTSTANDING STOCK AND OPTIONS

                           BIODELIVERY SCIENCES, INC.

<TABLE>
<CAPTION>
                                              Stock Purchased
Name                                            Under Delta            Total Stock Owned    BDSI Shares Post-Merger
-----                                         ----------------         -----------------    -----------------------
<S>                                           <C>                      <C>                  <C>
Raphael J. Mannino                                  500,000                  600,000             798,000
Susan Gould-Fogerite                                400,000                  500,000             665,000
Leila Zarif                                         500,000                  500,000             665,000
Albany Medical College                                    0                    7,300               9,709
University of Medicine and Dentistry of                   0                    7,300               9,709
New Jersey
John Michael Tramont                                 10,000                   35,000              46,550
Ruying Lu                                            15,000                   15,000              19,950
Ignacio Segarra                                      12,500                   12,500              16,625
Zi-Wei Chen                                          10,000                   10,000              13,300
Joan Hudock                                           7,500                    7,500               9,975
Johanna Casanovas                                     7,500                    7,500               9,975
Diane Hyra                                            7,500                    7,500               9,975

Biodelivery Sciences International, Inc.                  0                  175,000                   0
</TABLE>

Biodelivery Sciences International, Inc. also owns 210,006 shares of Series A
Convertible Preferred Stock of Biodelivery Sciences, Inc. which is convertible
into 10,500,300 shares of Common Stock of Biodelivery Sciences, Inc. These
shares will be cancelled in the Merger.

<PAGE>   24
                                                                              23

                                  SCHEDULE 3.3
                             No Breach or Violation

                                      None.

<PAGE>   25
                                                                              24

                                  SCHEDULE 3.4
                             Approvals and Consents

         None. BDSI will provide all notices required under the settlement with
Irv Berstein.

<PAGE>   26
                                                                              25

                                  SCHEDULE 3.8
                                 Capitalization

3.8(a) None.

3.8(b) BDSI is in the process of adopting a stock option plan, which will
reserve 2,500,000 shares of common stock. Additionally, BDSI has agreed to issue
shares of BDSI authorized but unissued Common Stock to satisfy certain past
due BDS obligations to the University of Medicine and Dentistry of New Jersey.

<PAGE>   27
                                                                              26

                                  SCHEDULE 3.10

BDSI has entered into agreements with Tatton Technology, LLC. RetinaPharma, Inc.
and Biotech Specialty Partners, LLC. Each of these entities is affiliated with
shareholders and members of management of BDSI. Copies of these agreements are
available for inspection at the offices, of BDS.<PAGE>   1
                                                                    EXHIBIT 10.2

                       SETTLEMENT AND SECURITY AGREEMENT

         WHEREAS Irving A. Berstein ("Berstein"), Jonathan L. Berstein and
Robert L. Berstein (collectively, the "Bersteins") are shareholders of
Biodelivery Sciences, Inc. ("BDS");

         WHEREAS, at various times, Berstein and/or Berstein Technology
Corporation ("BTC") entered into agreements with BDS, including, but not limited
to, a Consulting Agreement dated as of July 1, 1995, a Consulting Agreement
dated as of January 1996, and a Deferred Compensation Agreement (collectively,
together with any other agreements or relationships with BDS and/or BDSI, the
"Berstein Agreements");

         WHEREAS the Bersteins and BTC commenced an action against BDS and
certain of its officers and directors in the United States District Court for
the District of New Jersey (the "Court") entitled Berstein, et al. v. Mannino,
et al., Civil Action No. 99-5786 (the "Action");

         WHEREAS, BDS asserted various counterclaims in the Action against
Berstein and BTC (the "Counterclaims");

         WHEREAS, without admitting the validity of any claims, Counterclaims or
defenses in the Action, the parties are desirous of settling the litigation
between and among them, which would be expensive, burdensome and distracting,
and to put to rest all disputes between them; and

         WHEREAS the Bersteins are desirous of selling their shares in BDS to
Biodelivery Sciences International Inc. ("BDSI") (formerly MAS Acquisition XXIII
Corp., an Indiana corporation) and BDSI is desirous of purchasing those shares;

         NOW, in consideration of the promises and payments contained herein,
the parties agree as follows:

<PAGE>   2

         1.       BDS.and BDSI agree to pay the Bersteins and BTC the aggregate
sum of $275,000, payable as follows:

                  (a)      Upon the execution of this agreement by the last
party to sign (the "Execution Date"), BDS will pay to Cureton Caplan Hunt
Scaramella & Clark, P.C., as attorneys for the Bersteins and BTC, the sum of
$150,000; and

                  (b)      BDS and BDSI will pay the aggregate sum of $125,000,
together with interest at the rate of 9% per annum, in 12 monthly installments
payable to the Bersteins in accordance with the terms of the promissory note
(the "BDS Note") annexed hereto as Exhibit B. The monthly installment payments
shall be made by wire transfer in accordance with written instructions provided
by Cureton Caplan Hunt Scaramella & Clark, P.C. Any changes in those
instructions thereafter shall be in writing, signed by all of the Bersteins, and
must be received by BDS and BDSI not less than three business days before the
next payment is due. Payments will be accelerated in accordance with the terms
and conditions provided in the BDS Note.

         2.       Upon payment of the amount in paragraphs 1 (a) and 4(a), the
parties will instruct their attorneys to enter into and file a stipulation for
the dismissal of the claims and Counterclaims in the Action with prejudice and
without costs to any party, in the form annexed hereto as Exhibit A (the
"Stipulation of Dismissal").

         3.       The Bersteins represent that they are the sole owners of an
aggregate of 175,000 shares of BDS (together with any and all other interests,
claims or entitlements to securities of BDS, collectively, the "Berstein
Shares"); that they have not sold, transferred, pledged or granted any interest
in the Berstein Shares to any other person; that they own, and will transfer
pursuant to this agreement the Berstein Shares

                                       2
<PAGE>   3

free of any adverse claim; and that they have no other interest in any
securities of BDS or BDSI.

         4.       The Bersteins agree to sell, and BDSI agrees to purchase, the
Berstein Shares for the aggregate sum of $500,000, payable as follows:

                  (a)      upon the execution of this Agreement, BDS and BDSI
will pay to Cureton Caplan Hunt Scaramella & Clark P.C., as attorneys for the
Bersteins, the sum of $200,000, at which time the Bersteins shall sell, convey
and deliver all right, title and interest in and to the Berstein Shares to BDSI;
and

                  (b)      BDS and BDSI will pay the aggregate sum of $300,000,
together with interest at the rate of 9% per annum, in 36 monthly installments
payable to the Bersteins in accordance with the terms of the promissory note
(the "Shares Note") annexed hereto as Exhibit C. The monthly installment
payments shall be made by wire transfer in accordance with written instructions
provided by Cureton Caplan Hunt Scaramella & Clark, P.C. Any changes in those
instructions thereafter shall be in writing, signed by all of the Bersteins, and
must be received by BDS not less than three business days before the next
payment is due. Payments will be accelerated in accordance with the terms and
conditions provided for in the Shares Note.

         5.       For so long as any portion of the BDS Note or the Shares Note
or any portion due under this Settlement Agreement remains outstanding, BDS
grants to the Bersteins a first lien and security interest in all of the
tangible and intangible assets of BDS that are now currently held ("the BDS
Assets") including, but not limited to, (a) its license agreements with the
University of Medicine and Dentistry of New Jersey ("UMDNJ") (including the
License Agreement between UMDNJ and Albany Medical

                                       3
<PAGE>   4

College, and BDS, dated September 26, 1995), and (b) all equipment currently
owned by BDS, which are identified in the annexed Exhibit D, together with all
proceeds thereof, if any. BDS represents and warrants that it has title to the
BDS Assets; that there is currently no lien or security interest senior to the
security interest being granted to the Bersteins in the BDS Assets; and that it
has full authority and all necessary consents to grant such security interest to
the Bersteins. Copies of the UCC-1s which the Bersteins are authorized to file
are annexed as Exhibit E. A copy of the notice which the Bersteins are
authorized to file with the United States Patent and Trademark Office (the
"Patent Office Notice") is annexed as Exhibit F. BDS and BDSI agree to grant any
further consents and execute any documents necessary to enable the Bersteins to
perfect such liens or security interests in the BDS Assets.

         6.       The parties agree that this Agreement is subject to the
condition that the Bersteins enter into a Memorandum of Understanding with UMDNJ
and Albany Medical College acceptable to the Bersteins, BDS and BDSI,
substantially in the form annexed hereto as Exhibit G, concerning an option to
develop certain of BDS's intellectual property. Provided that the Bersteins
comply with the terms of this Agreement, BDS, BDSI and the individual
signatories to this Agreement (other than the Bersteins) agree not to challenge
or otherwise interfere with any of the rights granted by the Memorandum of
Understanding.

         7.       Simultaneously with the execution of this Settlement
Agreement, counsel for BDS and BDSI shall deliver to counsel for the Bersteins
an executed copy of the Consent Judgment in the form annexed hereto as Exhibit
H. Counsel for the Bersteins shall hold such Consent Judgment in escrow and may
file the same with the

                                       4
<PAGE>   5

Court only as provided and permitted pursuant to paragraph 9 of this Settlement
Agreement. Upon the satisfaction of the BDS Note and the Shares Note, (i)
counsel for the Bersteins shall return to counsel for BDS and BDSI the executed
Consent Judgment and (ii) the Bersteins shall provide BDS and BDSI with
evidence, satisfactory to BDS's and BDSI's counsel, that they have withdrawn or
revoked the Patent Office Notice.

         8.       The Court shall retain jurisdiction to enforce and interpret
the terms of this Settlement Agreement and, for that purpose, BDSI consents to
the jurisdiction of the Court.

         9.       (a) Payment of the BDS Note and the Shares Note shall be due
and payable on the first of each month, commencing May 1, 2001. If payment has
not been received by the fifth of any month during the term of either the BDS
Note or the Shares Note, then (i) BDS and/or BDSI shall also pay an amount equal
to 5% of the overdue payment as a "Late Payment Charge"; and (ii) the Bersteins
may send notice of such non-payment to BDS and/or BDSI (the date upon which such
notice is actually sent shall be the "Notice Date"). BDS and BDSI shall have ten
days from the Notice Date (provided that the tenth day is not a Saturday, Sunday
or bank holiday, in which case, BDS and BDSI shall have until the next business
day thereafter) to make payment of that monthly installment, together with any
Late Payment Charge (the "Cure Period"). Following the expiration of the Cure
Period, the BDS Note and/or the Shares Note, as the case may be, shall
accelerate and be due and payable in full. In the event of three successive late
payments, the right to cure shall thereafter no longer be available to BDS and
BDSI.

                                       5
<PAGE>   6

                  (b)      If the BDS Note and/or the Shares Note, as the case
may be, is not paid in full by the twentieth day following the expiration of the
Cure Period (Provided that the twentieth day is not a Saturday, Sunday or bank
holiday, in which case, BDS and BDSI shall have until the next business day
thereafter), the Bersteins may file with the Court the executed Consent Judgment
(completed to reflect accurately the then existing amounts due from BDS and/or
BDSL respectively), together with an affidavit, executed under oath, by any one
of the Bersteins (the "Affidavit") attesting to (i) the giving of timely and
appropriate notice by the Bersteins as required in paragraphs 9 and 14 of this
Agreement, (ii) the failure of BDS and/or BDSI to make payment on a timely basis
in accordance with paragraph 9 of this Agreement; (iii) the failure of BDS
and/or BDSI to make timely cure in accordance with paragraph 9 of this
Agreement; (iv) compliance by the Bersteins with this Settlement Agreement; and
(v) an accurate statement of the amount then due and payable. The Bersteins
shall provide BDS and BDSI with written notice of the filing of the Consent
Judgment and a copy of the supporting affidavit at the time that it is filed,
whereupon, unless the Court shall direct otherwise, the Bersteins shall have all
the rights, and be subject to all of the responsibilities of a judgment creditor
under the Uniform Commercial Code. Except with the consent of the Bersteins,
which they may withhold in their sole discretion, neither BDS, BDSI, the
defendants in the Action nor their parents, subsidiaries, affiliates, successors
or assigns may bid for the BDS Assets at a sale which has been ordered by the
Court or by any bankruptcy court in which BDS or BDSI is the debtor.

                  (c)      BDS and BDSI shall have the unqualified and
irrevocable right to redeem the BDS Assets upon the payment in full of the
amount then due and

                                       6
<PAGE>   7

payable on the BDS Note and/or the Share Note, together with interest, Late
Payment Charges, and reasonable costs of collection, including, but not limited
to, the Bersteins' reasonable attorneys' fees and litigation expenses, which
right of redemption shall expire upon the day following the filing of the
Affidavit and Consent Judgment, unless extended by order of the Court.

         10.      BDS and BDSI, respectively, represents and warrants that they
are not insolvent, as that term is defined in 11 U.S.C. ss. 101 (32), and that
neither intends to file a petition under the Bankruptcy Code within 120 days of
the date of this Agreement. Simultaneously with the execution of this Settlement
Agreement, Raphael Mannino, Susan Gould Fogerite, Leila Zarif, Donald L.
Ferguson and Francis E. O'Donnell will deliver to the Bersteins the Undertaking
and Guaranty annexed hereto as Exhibit 1.

         11.      BDS and BDSI agree that if they merge or transfer between them
substantially all of their respective assets, then they shall give the Bersteins
notice of the consummation of such transaction within ten days of such
consummation.

         12.      This Agreement supersedes any and all other agreements and
relationships between the Bersteins or BTC, and BDS or BDSI, including, but not
necessarily limited to, the Berstein Agreements, which are hereafter null and
void, and the Bersteins shall have no right, title, claim, entitlement,
receivable or interest of any nature against BDS or BDSI or their assets or
securities except pursuant to this Settlement Agreement, the BDS Note and the
Shares Note.

         13.      Except for the representations, promises and obligations
contained herein and in such other documents executed hereunder, the Bersteins
and BTC hereby release and discharge BDS and BDSI and each of their respective
present and former

                                       7
<PAGE>   8

parents, subsidiaries, affiliates, members, predecessors, successors and
assigns, shareholders, directors, officers, employees, representatives and
agents, as applicable (including, but not limited to, Raphael Mannino, Susan
Gould Fogerite, Leila Zarif, Edmund Tramont, Timothy Surginor, Frank O'Donnell,
Sam Duffey and Don Ferguson), (collectively, the "BDS RELEASEES"), from all
actions, causes of action, contracts, damages, judgments, executions, and claims
of any kind whatsoever, in law or equity, which the Bersteins and BTC and their
respective present and former parents, subsidiaries, affiliates, predecessors,
heirs, executors, administrators, successors and assigns, as applicable, ever
had, now have or hereafter can, shall or may have against the BDS RELEASEES,
from the beginning of the world up until the date of this release, for, upon or
by reason of any matter, cause or thing whatsoever.

         14.      Except for the representations promises and obligations
contained herein and in such other documents executed hereunder, BDS and BDSL
Raphael Mannino, Susan Gould Fogerite, Leila Zarif, Edmund Tramont, Timothy
Surginor, Frank O'Donnell, Sam Duffey and Don Ferguson (collectively, the "BDS
RELEASORS") hereby release and discharge the Bersteins and BTC, and each of
their respective present and former parents, subsidiaries, affiliates, members,
predecessors, successors and assigns, shareholders, directors, officers,
employees, representatives and agents, as applicable (collectively, the
"Berstein RELEASEES"), from all actions, causes of action, contracts, damages,
judgments, executions, and claims of any kind whatsoever, in law or equity,
which the BDS RELEASORS and their respective present and former parents,
subsidiaries, affiliates, predecessors, heirs, executors, administrators,
successors and assigns, as applicable, ever had, now have or hereafter can,
shall or may have against the

                                       8
<PAGE>   9

Berstein RELEASEES, from the beginning of the world up until the date of this
release, for, upon or by reason of any matter, cause or thing whatsoever.

         15.      Any notice to BDS or BDSI under this Settlement Agreement or
the related BDS Note or Share Note shall be sent by certified mail, return
receipt requested, to:

                  Biodelivery Sciences, Inc.
                  Biodelivery Sciences International
                  UMDNJ New Jersey Medical School
                  185 So. Orange Avenue - Building 4
                  Newark, New Jersey 07103

with a copy faxed or hand delivered to:

                  Bruce H. Schneider, Esq.
                  Melvin Epstein, Esq.
                  Stroock & Stroock & Lavan LLP
                  180 Maiden Lane
                  New York, New York 10038
                  Phone: (212) 806-5400
                  Fax: (212) 806-6006
                  -and-

                  Don Ferguson
                  11710 Old Ballas Road - Suite 110
                  St. Louis, Missouri 63141
                  Phone: (314) 569-3539
                  Fax: (314) 569-3867

Any notice to the Bersteins under this Settlement Agreement or the related BDS
Note or Share Note shall be sent by certified mail, return receipt requested,
to:

                  Irving Berstein
                  Berstein Technology Corp.
                  42 Buckman Drive
                  Lexington, Massachusetts 02421

with a copy faxed or hand delivered to:

                  Carlo Scaramella, Esq.
                  Cureton Caplan Hunt Scaramella & Clark, P C
                  950B Chester Avenue
                  Delran, NJ 08075
                  Phone: (856) 824-1001
                  Fax: (856)-824-1008

                                       9
<PAGE>   10

and a copy sent by overnight delivery to:

                  Robert L. Berstein
                  28 W. 76th Street
                  New York, New York 10023

         16. This Agreement constitutes the entire agreement of the parties
regarding the subject matter hereof, superseding all prior understandings,
whether oral or in writing. This Agreement may be modified only in a writing
signed by the parties whose obligations hereunder will be affected by the
modifications.

         17.      This Agreement shall be construed in accordance with the laws
of the State of New Jersey, without giving effect to that state's choice of law
rules.

         18.      This Agreement may be executed in one or more counterparts,
and by the parties hereto in separate counterparts, each of which shall be
deemed to be an original, but all of which together shall constitute one and the
same agreement.

Dated: March___, 2001       ------------------------------
                            IRVING A. BERSTEIN

Dated: March___, 2001       ------------------------------
                            JONATHAN L. BERSTEIN

Dated: April 25, 2001       ------------------------------
                            ROBERT L. BERSTEIN

Dated: March_, 2001         BERSTEIN TECHNOLOGY CORPORATION

By:
   ------------------------------

Title:
      ---------------------------

Dated: March__,2001           ----------------------------
                              RAPHAEL MANNINO

                                       10
<PAGE>   11

Dated: March 2001           -----------------------------
                            SUSAN GOULD FOGERITE

Dated: March 2001           -----------------------------
                            LEELA ZARIF

Dated: March_, 2001         -----------------------------
                            EDMUND TRAMONT

                                       11
<PAGE>   12
Dated: March __, 2001      BIODELIVERY SCIENCES, INC

By: ______________________

Title: ___________________

Dated: March __, 2001      BIODELIVERY SCIENCES INTERNATIONAL, INC.

By: ______________________

Title: ___________________

Dated: March __, 2001
                           ----------------------------------
                           TIMOTHY SURGINOR

Dated: March __, 2001
                           ----------------------------------
                           FRANK O'DONNELL

Dated: March __, 2001      /s/ Sam Duffey
                           ----------------------------------
                           SAM DUFFEY

Dated: March __, 2001
                           ----------------------------------
                           DON FERGUSON

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]